Oral caffeine administration ameliorates acute colitis by suppressing chitinase 3-like 1 expression in intestinal epithelial cells

Journal of Gastroenterology

Volumn 49, Issue 8, 2014, Pages 1206-1216

  Lee, In Ah ^a   Low, Daren ^a   Kamba, Alan ^a   Llado, Victoria ^a   Mizoguchi, Emiko ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

AKT; Chitinase inhibitor; Host microbial interactions; Inflammatory bowel disease

Indexed keywords

ADIPOCYTOKINE; CAFFEINE; CHI3L1 PROTEIN, HUMAN; DEXTRAN SULFATE; LECTIN; MESSENGER RNA;

ACUTE DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; BACTERIAL TRANSLOCATION; C57BL MOUSE; CELL LINE; COLITIS; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; GENETICS; INTESTINE MUCOSA; MALE; METABOLISM; MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY;

ACUTE DISEASE; ADIPOKINES; ADMINISTRATION, ORAL; ANIMALS; BACTERIAL TRANSLOCATION; CAFFEINE; CELL LINE; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; INTESTINAL MUCOSA; LECTINS; MALE; MICE; MICE, INBRED C57BL; RNA, MESSENGER;

EID: 84905698762     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0865-3     Document Type: Article

References (28)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-34. (Pubitemid 47123518)
2. Hamilton MJ, Snapper SB, Blumberg RS. Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance. J Gastroenterol. 2012;47(1):1-8.
3. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42(12):1118-25.
4. Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T, et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet. 2008;40(6):713-5. (Pubitemid 351748866)
5. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43(3):246-52.
6. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119-24.
7. Mizoguchi E. Chitinase 3-like-1 exacerbates intestinal inflammation by enhancing bacterial adhesion and invasion in colonic epithelial cells. Gastroenterology. 2006;130(2):398-411. (Pubitemid 43202039)
8. Chen CC, Llado V, Eurich K, Tran HT, Mizoguchi E. Carbohydrate-binding motif in chitinase 3-like 1 (CHI3L1/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cells. Clin Immunol. 2011;140(3):268-75.
9. Schuttelkopf AW, Andersen OA, Rao FV, Allwood M, Lloyd C, Eggleston IM, et al. Screening-based discovery and structural dissection of a novel family 18 chitinase inhibitor. J Biol Chem. 2006;281(37):27278-85. (Pubitemid 44401755)
10. Koyama R, Kataoka H, Tanaka Y, Nakatsugi S, Furukawa M. Effect of caffeine on ibuprofen-induced gastric mucosal damage in rats. J Pharm Pharmacol. 1999;51(7):817-24. (Pubitemid 29377954)
11. Ford AC, Moayyedi P, Hanauer SB. Ulcerative colitis. BMJ. 2013;346:f432.
12. Verheijden GF, Rijnders AW, Bos E, Coenen-de Roo CJ, van Staveren CJ, Miltenburg AM, et al. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum. 1997;40(6):1115-25. (Pubitemid 27242299)
13. Bara I, Ozier A, Girodet PO, Carvalho G, Cattiaux J, Begueret H, et al. Role of YKL-40 in bronchial smooth muscle remodeling in asthma. Am J Respir Crit Care Med. 2012;185(7):715-22.
14. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283(20):2674-9. (Pubitemid 30337329)
15. Altman RD, Lang AE, Postuma RB. Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord. 2011;26(13):2427-31.
16. Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology. 2012;79(7):651-8.
17. Chen JF, Chern Y. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies. Handb Exp Pharmacol. 2011;200:267-310.
18. Andersen LF, Jacobs DR Jr, Carlsen MH, Blomhoff R. Consumption of coffee is associated with reduced risk of death attributed to inflammatory and cardiovascular diseases in the Iowa Women's Health Study. Am J Clin Nutr. 2006;83(5):1039-46. (Pubitemid 44713102)
19. Ku BM, Lee YK, Jeong JY, Ryu J, Choi J, Kim JS, et al. Caffeine inhibits cell proliferation and regulates PKA/GSK3beta pathways in U87MG human glioma cells. Mol Cells. 2011;31(3):275-9.
20. Eurich K, Segawa M, Toei-Shimizu S, Mizoguchi E. Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol. 2009;15(42):5249-59.
21. Chen CC, Pekow J, Llado V, Kanneganti M, Lau CW, Mizoguchi A, et al. Chitinase 3-like-1 expression in colonic epithelial cells as a potentially novel marker for colitis-associated neoplasia. Am J Pathol. 2011;179(3):1494-503.
22. Keum B, Jeen YT, Park SC, Seo YS, Kim YS, Chun HJ, et al. Proctocolitis caused by coffee enemas. Am J Gastroenterol. 2010;105(1):229-30.
23. Lee CJ, Song SK, Jeon JH, Sung MK, Cheung DY, Kim JI, et al. Coffee enema induced acute colitis. Korean J Gastroenterol. 2008;52(4):251-4.
24. Margolin KA, Green MR. Polymicrobial enteric septicemia from coffee enemas. West J Med. 1984;140(3):460.
25. Eisele JW, Reay DT. Deaths related to coffee enemas. JAMA. 1980;244(14):1608-9. (Pubitemid 10059820)
26. Teekachunhatean S, Tosri N, Rojanasthien N, Srichairatanakool S, Sangdee C. Pharmacokinetics of caffeine following a single administration of coffee enema versus oral coffee consumption in healthy male subjects. ISRN Pharmacol. 2013;2013:147238.
27. Bott C, Rudolph MW, Schneider AR, Schirrmacher S, Skalsky B, Petereit HU, et al. In vivo evaluation of a novel pH- and time-based multiunit colonic drug delivery system. Aliment Pharmacol Ther. 2004;20(3):347-53. (Pubitemid 39062138)
28. Muraoka M, Hu Z, Shimokawa T, Sekino S, Kurogoshi R, Kuboi Y, et al. Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. J Control Release. 1998;52(1-2):119-29. (Pubitemid 28123179)